BeOne Medicines Ltd. - Sponsored ADR (ONC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended September 2025, BeOne Medicines Ltd. - Sponsored ADR (ONC) reported revenue of $1.41 billion, up 41% over the same period last year. EPS came in at $1.09, compared to -$1.15 in the year-ago quarter.

The reported revenue represents a surprise of +5.36% over the Zacks Consensus Estimate of $1.34 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +51.39%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how BeOne Medicines Ltd. - Sponsored ADR performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Product Revenue- TEVIMBRA: $190.62 million versus $198.95 million estimated by three analysts on average.
• Revenues- Product Revenue- BRUKINSA(Zanubrutinib): $1.04 billion versus the three-analyst average estimate of $1.01 billion.
• Revenues- Net product revenues: $1.4 billion versus $1.35 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +40.4% change.
• Revenues- Product Revenue- KYPROLIS: $18.37 million compared to the $20.11 million average estimate based on two analysts.
• Revenues- Product Revenue- BLINCYTO: $30.48 million versus the two-analyst average estimate of $25.67 million.
• Revenues- Product Revenue- POBEVCY: $10.5 million versus the two-analyst average estimate of $12.33 million.
• Revenues- Product Revenue- Other: $20.11 million versus $17.76 million estimated by two analysts on average.
• Revenues- Product Revenue- XGEVA: $84.24 million compared to the $66.23 million average estimate based on two analysts.

View all Key Company Metrics for BeOne Medicines Ltd. - Sponsored ADR here>>>

Shares of BeOne Medicines Ltd. - Sponsored ADR have returned -8.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
BeOne Medicines Ltd. - Sponsored ADR (ONC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research